Last but not least, neither ideal biomarkers nor therapeutic targets are currently available for slowly progressive CMT, although we do have some promising candidates to target in the diagnosis and treatment of CMT, such as Nrp‐1, TRIM28 and nuclear TyrRS. The gene discussed is NRP1; the disease is Charcot-Marie-Tooth disease.